Graves’ disease is an autoimmune condition that leads to an overactive thyroid gland. Image credit: Shutterstock / Jo Panuwat D. Immunovant has reported positive results from a trial investigating its ...
VRDN-003 is under clinical development by Viridian Therapeutics and currently in Phase I for Graves’ Ophthalmopathy. According to GlobalData, Phase I drugs for Graves’ Ophthalmopathy have a 100% phase ...